A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...

NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorabl ...

Meta-analysis of data from FDA trials shows significantly improved OS, PFS, but increased risk for grade ≥3 adverse events compared with men ...

The earliest indicator of bladder cancer is the presence of blood in the urine. At later stages, the illness may be accompanied by pain in the flank, pelvis, and weight loss ...

Relmada Therapeutics(NASDAQ:RLMD) reported that clinical progress for NDV01 includes durable, high 12-month complete response rates in both broad and BCG-unresponsive NMIBC populations, with favorable ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...

A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten ...